Adilijiang Maimaitiming^*, Ailijiang Wusiman^†, Abulajiang Aimudula^†, Xuekelaiti Kuerban^*, Pengcheng Su^*

Oncology Research, Vol.28, No.1, pp. 13-19, 2020, DOI:10.3727/096504019X15519249902838

Abstract The aim of the present study was to investigate the roles of microRNA-152 (miR-152) in the initiation and progression of breast cancer. The expression level of miR-152 was detected in human breast cancer tissue and a panel of human breast cancer cell lines using qRT-PCR. Results found that miR-152 expression was significantly downregulated in breast cancer tissue samples compared to adjacent noncancerous tissues as well as in breast cancer cell lines. Overexpression of miR-152 significantly suppressed breast cancer cell proliferation, migration, and invasion. Luciferase reporter assay results found that ROCK1 is a direct and functional target gene of miR-152 in… More >

Xiangbin Tan^*1, Zefei Liao^†1, Shuangyou Zou^*, Liangyun Ma^†, Aimin Wang^*

Oncology Research, Vol.28, No.1, pp. 3-11, 2020, DOI:10.3727/096504019X15509383469698

Abstract Vasohibin2 (VASH2), a proangiogenic factor, has been demonstrated to play an oncogenic role in some common human cancers. However, the detailed function of VASH2 in non-small cell lung cancer (NSCLC) has not previously been studied. In this study, we found that VASH2 was significantly upregulated in NSCLC tissues and cell lines, and its increased expression was associated with NSCLC progression and poor prognosis of patients. Knockdown of VASH2 markedly inhibited cell proliferation and P-glycoprotein expression in NSCLC cells. Overexpression of VASH2 enhanced cell proliferation, P-glycoprotein expression, as well as doxorubicin resistance in NSCLC cells. Moreover, the expression levels of VASH2… More >

Kazuo Umezawa

Oncology Research, Vol.28, No.1, pp. 1-1, 2020, DOI:10.3727/096504020X15795276404798

Abstract This article has no abstract. More >

Jianjun Shen^*, Weina Niu^†, Hongbo Zhang^*, Ma Jun^*, Hongyan Zhang^*

Oncology Research, Vol.29, No.1, pp. 79-79, 2021, DOI:10.3727/096504022X16491544361323

Abstract This article has no abstract. More >

Jianping Xu, Liguo Sun, Wei Sun, Jianhai Tian, Huaiyuan Guo

Oncology Research, Vol.29, No.1, pp. 77-77, 2021, DOI:10.3727/096504022X16425915715943

Abstract This article has no abstract. More >

Hai-Feng Zeng^*, Hai-Yan Qiu^†, Fa-Bo Feng^*

Oncology Research, Vol.29, No.1, pp. 75-75, 2021, DOI:10.3727/096504022X16420719767471

Abstract This article has no abstract. More >

Yudie Yang^*1, Xia Zhang^†1, Yajie Gao^*, Yan Dong^*, Di Wang^*, Yanping Huang^*, Tianhao Qu^*, Buqun Fan^*, Qizheng Li^*, Chunxia Zhang^*, Xiaonan Cui^*, Bin Zhang^*

Oncology Research, Vol.29, No.1, pp. 63-74, 2021, DOI:10.3727/096504022X16462176651719

Abstract Lung cancer is a malignant tumor with high incidence and mortality across the world. The use of immune checkpoint inhibitors for lung cancer has improved the prognosis of some lung cancer patients to a greater extent and provided a new direction for the clinical treatment of lung cancer. Immunotherapy still has limitations in terms of its appropriate population and adverse reactions. Particularly for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation, there has been no major breakthrough in current immunotherapy. Whether immunotherapy can bring new benefits after drug resistance is induced by tyrosine kinase inhibitor-targeted… More >

Hsiang-Lin Tsai^*†, Yen-Cheng Chen^*‡, Tzu-Chieh Yin^*§¶, Wei-Chih Su^*‡, Po-Jung Chen^*,Tsung-Kun Chang^*†, Ching-Chun Li^*, Ching-Wen Huang^*†, Jaw-Yuan Wang^{*†‡#**††‡‡}

Oncology Research, Vol.29, No.1, pp. 47-61, 2021, DOI:10.3727/096504022X16451187313084

Abstract Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type metastatic colorectal cancer (mCRC) patients treated with cetuximab or bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation as the first-line therapy. In total, 173 patients with mCRC with RAS wild-type were enrolled. Among them, 98 patients were treated with cetuximab, whereas 75 patients were treated with bevacizumab. All patients received irinotecan dose escalation based on UGT1A1 genotyping. We compared the progression-free survival (PFS),… More >

Angela Silvano^*†1, Giulio Menegazzi^*1, Silvia Peppicelli^*1, Caterina Mancini^*, Alessio Biagioni^*, Alessandro Tubita^*, Ignazia Tusa^*, Jessica Ruzzolini^*, Matteo Lulli^*, Elisabetta Rovida^*, Persio Dello Sbarba^*

Oncology Research, Vol.29, No.1, pp. 33-46, 2021, DOI:10.3727/096504022X16442289212164

Abstract This study was directed to deepen the effects of nutrient shortage on BCR/Ablprotein expression and signaling in chronic myeloid leukemia (CML) cells. The backbone of the study was cell culture in medium lacking glucose, the consumption of which we had previously shown to drive BCR/Ablprotein suppression, and glutamine, the other main nutrient besides glucose. In this context, we focused on the role of lactate, the main by-product of glucose metabolism under conditions of rapid cell growth, in particular as a modulator of the maintenance of CML stem/progenitor cell potential, a crucial determinant of disease course and relapse of disease. The… More >

Shuai Liu^*†1, Lu Lu^*†1, Feng Pan^‡, Chunsheng Yang^*†, Jing Liang^§, Jinfeng Liu^¶, Jian Wang^#, Rong Shen^**, Fu-Ze Xin^††, Nan Zhang^*†

Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672

Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd., Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients. We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free survival (PFS) was evaluated using the… More >